Psychiatric Services
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Menzin, J.
* Articles by Lloyd, J. R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Menzin, J.
* Articles by Lloyd, J. R.
Related Collections
* Treatment Compliance
* Atypical Neuroleptics
* Conventional Neuroleptics
* Schizophrenia Spectrum Disorders
Psychiatr Serv 54:719-723, May 2003
© 2003 American Psychiatric Association


Other Articles

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

Joseph Menzin, Ph.D., Luke Boulanger, M.A., Mark Friedman, M.D., Joan Mackell, Ph.D. and John R. Lloyd, B.S.

OBJECTIVES: Rates of medication adherence over a one-year period were assessed among outpatients with schizophrenia who initiated therapy with conventional or atypical antipsychotic agents. METHODS: Data were drawn from paid medical and pharmacy claims for a random sample of 10 percent of all California Medicaid ("Medi-Cal") recipients. Outpatients with schizophrenia who were aged 18 years or older and who initiated monotherapy with a conventional or atypical antipsychotic medication in the last quarter of 1997 were identified. The percentages of patients who discontinued antipsychotic therapy or who had a switch in medications over a one-year period were determined. The use of selected concomitant medications was also assessed. Data were analyzed by means of chi square tests and multivariate statistics that adjusted for demographic and clinical differences between medication groups. RESULTS: A total of 298 patients who initiated therapy with a conventional (N=93) or atypical (N=205) antipsychotic medication were identified. The groups were similar in mean age (about 42 years) and gender distribution (about 54 percent were male). Compared with patients who received conventional antipsychotics, those receiving atypical antipsychotics were significantly less likely to have a switch in medication and to use concomitant anticholinergic and anxiolytic medications. In each group, antipsychotic medication was available for about 60 percent of days over one year of follow-up. CONCLUSIONS: Compared with the use of conventional antipsychotics, the use of atypical antipsychotic medications was associated with significantly less treatment switching and less use of concomitant medications. However, undertreatment, evidenced by a lack of prescription refills, occurred among patients taking both medication classes, which highlights the need for further research on nonadherence.




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
M. Hassan, S S. Madhavan, I. D Kalsekar, E. H Makela, K. Rajagopalan, S. Islam, J. Kavookjian, and L.-A. Miller
Comparing Adherence to and Persistence with Antipsychotic Therapy Among Patients with Bipolar Disorder
Ann. Pharmacother., November 1, 2007; 41(11): 1812 - 1818.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
D. I. Velligan, M. Wang, P. Diamond, D. C. Glahn, D. Castillo, S. Bendle, Y. W. F. Lam, L. Ereshefsky, and A. L. Miller
Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications
Psychiatr Serv, September 1, 2007; 58(9): 1187 - 1192.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. C. Singh, A. J. Massey, M. D. Thompson, L. R. Rappa, and M. S. Honeywell
Addressing Nonadherence in the Schizophrenic Population
Journal of Pharmacy Practice, December 1, 2006; 19(6): 361 - 368.
[Abstract] [PDF]


Home page
Schizophr BullHome page
D. I. Velligan, Y.-W. F. Lam, D. C. Glahn, J. A. Barrett, N. J. Maples, L. Ereshefsky, and A. L. Miller
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature
Schizophr Bull, October 1, 2006; 32(4): 724 - 742.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Am J Psychiatry, March 1, 2006; 163(3): 396 - 401.
[Abstract] [Full Text] [PDF]


Home page
Psychiatr. Serv.Home page
D. S. Srebnik, L. T. Rutherford, T. Peto, J. Russo, E. Zick, C. Jaffe, and P. Holtzheimer
The Content and Clinical Utility of Psychiatric Advance Directives
Psychiatr Serv, May 1, 2005; 56(5): 592 - 598.
[Abstract] [Full Text] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org